Targeted cancer therapies are associated with cardiovascular toxicities such as decreased ejection fraction and atrial arrhythmias.
Requires CV monitoring with targeted cancer therapies; extends the evidence base on therapy-specific toxicities.
Agents targeting signaling pathways in cancer cells are less specific than advertised. A number of these agents induce cardiovascular toxic effects ranging from decreased ejection fraction to atrial arrhythmias.
No takes yet. Share an insight, caveat, or question.
Javid J. Moslehi (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: